Key Highlights
- Braden Parker appointed Chief Commercial Officer, effective immediately.
- Over 25 years of experience in biotech and healthcare, with a focus on rare disease products.
- Will lead Savara’s global commercial strategy for molgramostim in aPAP treatment.
- Former Chief Commercial Officer at Orchard Therapeutics, where he launched Libmeldy for metachromatic leukodystrophy.
- Molgramostim is in Phase 3 development and awaiting potential FDA approval.
Source: Business Wire
Notable Quotes
- “Braden is an accomplished leader with a proven track record of building commercial teams, leading successful rare disease product launches and accelerating growth for companies.” — Matt Pauls, Chair and CEO at Savara
- “I believe molgramostim, if approved, is uniquely positioned to make a significant impact in the treatment of aPAP.” — Braden Parker, Chief Commercial Officer at Savara
SoHC's Take
Savara’s decision to bring Braden Parker on board as Chief Commercial Officer signals a pivotal moment in the company’s transition toward commercialization. With a strong background in launching rare disease therapies, Parker’s expertise will be instrumental as Savara prepares for the potential FDA approval of molgramostim, which could become the first treatment for aPAP. His extensive experience with Orchard Therapeutics and PTC Therapeutics shows his proven ability to navigate complex global markets and bring innovative therapies to patients. This strategic appointment positions Savara for significant growth in the rare respiratory disease sector.
